Ibogaine for Suboxone: What the Evidence Shows

Suboxone combines buprenorphine, a high-affinity partial agonist at the mu-opioid receptor, with naloxone, an antagonist included to deter injection. Buprenorphine is also dispensed alone as Subutex and generic sublingual film, and as Sublocade, a monthly extended-release injection.

Two distinct things are routinely conflated here:

• Physical dependence on buprenorphine is expected and pharmacologically normal. Anyone taking a mu-opioid agonist daily will develop it. Wanting to avoid withdrawal is not, on its own, addiction.
• Opioid use disorder (OUD) is a behavioural diagnosis defined by compulsive use, loss of control, and continued use despite harm. The National Institute on Drug Abuse addresses the "substituting one addiction for another" concern directly: buprenorphine taken as prescribed prevents craving and withdrawal without producing the intense reward of full agonists.

There is no separate ICD-10 code for "Suboxone dependence." People maintained on buprenorphine are generally coded under the underlying disorder — F11.20 (opioid dependence, uncomplicated) or F11.21 (in remission) — not the medication.

Who searches for this. Roughly 5.7 million US adults were estimated to have OUD in 2023, and buprenorphine is the most commonly prescribed medication for it, with one analysis tracking about 2.4 million US adults filling prescriptions. Those seeking an exit tend to be people stabilised for years who want to be medication-free, people who started buprenorphine for pain rather than severe OUD, people who found tapering harder than expected, and people on Sublocade who cannot easily reverse the decision.

One pharmacological fact shapes everything below. Buprenorphine's high receptor affinity and slow, prolonged elimination are what make it an effective maintenance medication — and what make discontinuation slow and any ibogaine protocol complicated.

Conventional addiction medicine has a strong evidence base here, and it deserves accurate representation.

Continued maintenance is the best-evidenced option. Santo and colleagues (JAMA Psychiatry, 2021) pooled 15 randomised trials (3,852 people) and 36 cohort studies (749,634 people). Opioid agonist treatment was associated with more than a 50% reduction in all-cause mortality (RR 0.47), with buprenorphine specifically at RR 0.34. Crude mortality was 11 deaths per 1,000 person-years on treatment versus 23.97 off it.

The cessation window is where people die. The same analysis found all-cause mortality six times higher in the four weeks after stopping opioid agonist treatment (RR 6.01), and roughly double for the remainder of time off treatment (RR 1.81). This is the single most important number on this page.

Tapering outcomes are sobering. A review by Dunn and colleagues of 27 buprenorphine taper studies found a median of only 23% of participants opioid-negative at first post-taper follow-up. A systematic review by Bentzley and colleagues found relapse within one month exceeded 50% in every study, with only about 18% abstinent in that first month.

Other approaches include naltrexone-facilitated discontinuation, where small case series report encouraging results in patients who had previously failed to stop. Neither it nor structured behavioural support has large-scale outcome data for this transition.

Zweben and colleagues (Journal of Addiction Medicine, 2021) reviewed this literature and concluded that no predictive factors for successful tapering have been identified and that "a majority of patients will need to remain on medication to preserve their gains."

The honest summary: conventional treatment is genuinely good at keeping people alive and stable on buprenorphine, and genuinely weak at helping people who want to be off it. That gap is where interest in ibogaine for Suboxone concentrates.

Ibogaine is a psychoactive indole alkaloid from the root bark of Tabernanthe iboga. The property that draws attention is a repeatedly reported one: a single dose appears to attenuate opioid withdrawal within roughly 24–48 hours rather than over weeks.

The mechanism behind that observation is not established. What is known:

• Ibogaine is not a mu-opioid agonist. Maillet, Alper and colleagues (PLOS ONE, 2013) found that ibogaine, its metabolite noribogaine, and the analogue 18-MC behaved as mu-opioid receptor antagonists in rat thalamic membranes, with functional Ke values from about 3 µM (ibogaine) to 13 µM (noribogaine and 18-MC). The authors concluded that agonist action at the mu receptor does not account for the effect on withdrawal, implying a novel mechanism
• It also acts as a non-competitive antagonist at α3β4 nicotinic acetylcholine receptors, an NMDA channel blocker, and an inhibitor of serotonin and dopamine transport
• It is metabolised largely by CYP2D6 to noribogaine, whose long half-life shapes both duration of effect and risk
• Rodent work (He and Ron, FASEB Journal, 2006; Marton and colleagues, 2019) shows sustained upregulation of glial cell line-derived neurotrophic factor (GDNF) in dopaminergic circuits

Two evidence-level caveats apply directly to Suboxone:

• The 2026 scoping review in Molecules identifies rapid attenuation of opioid withdrawal as the one reproducible human signal, but reframes ibogaine "not as a viable therapeutic endpoint, but as a lead compound," with safer analogues such as 18-MC being pursued instead
• None of this work was conducted in buprenorphine-maintained animals or people. The preclinical models used morphine and other short-acting agonists

The most important statement in this section is a negative one: no published study has evaluated ibogaine specifically in buprenorphine- or Suboxone-maintained patients. The human literature concerns people dependent on short-acting opioids.

What does exist:

• Mash and colleagues (Frontiers in Pharmacology, 2018) reported an open-label case series of 191 participants (102 opioid-dependent). Withdrawal scores were significantly lower than baseline at 36 hours, and craving and depression scores improved. Critically, participants were switched at programme entry to morphine sulfate before dosing. One-month follow-up was available for only about 37–50% of opioid participants
• Brown and Alper (American Journal of Drug and Alcohol Abuse, 2018) followed 30 people with DSM-IV opioid dependence given a mean total dose of 1,540 ± 920 mg ibogaine HCl. Subjective Opioid Withdrawal Scale scores fell from 31.0 to 14.0 at about 76 hours. At one month, 15 of 30 (50%) reported no opioid use in the previous 30 days
• Noller, Frampton and Yazar-Klosinski (2018) followed 14 participants for 12 months, reporting significant reductions in Addiction Severity Index drug use scores (p = 0.002), depression (p < 0.001), and acute withdrawal (p = 0.015). One participant died during treatment

What this evidence does not establish:

• No randomised, placebo-controlled trial of ibogaine has been completed for opioid use disorder. The 2026 Molecules review states this without qualification
• Every cohort is small, open-label, unblinded, and self-selected. People who can pay for and travel to private clinics differ systematically from the general treatment population
• Loss to follow-up is severe, and abstinence outcomes are "inconsistently defined, heterogeneously measured, and rarely supported by biological confirmation"
• None of it addresses buprenorphine. Comparisons circulate contrasting ibogaine cohort abstinence rates against buprenorphine taper rates; these are not comparable populations, and no head-to-head study exists

Terasaki, Sackett and Monte made the risk explicit (Journal of Addiction Medicine, 2026): framing ibogaine as an alternative to rather than a complement to methadone and buprenorphine could increase overdose risk.

This is the question behind most searches for how long off Suboxone before ibogaine, and it has no validated answer.

Buprenorphine binds mu-opioid receptors with high affinity and dissociates slowly. The Clinical Guidelines for Ibogaine-Assisted Detoxification (Global Ibogaine Therapy Alliance, 2015–17), the most widely referenced non-regulatory protocol document, set out standard practice:

• People on long-acting opioids should first be transitioned to a short-acting opioid, preferably morphine sulfate
• The rationale is that dosing ibogaine while long-acting opioid remains in circulation risks analgesic potentiation — ibogaine increases CNS sensitivity to opioids — and residual withdrawal persisting after the session
• Residual-dose target before dosing: no more than roughly 0.125 mg buprenorphine (and about 2 mg methadone)
• Assuming a 24-hour half-life, 4 mg/day buprenorphine clears by about day 6; assuming a conservative 72-hour half-life, the same dose requires 18 or more days — the approach recommended for long-term users and poor metabolisers
• The switch must be gradual and medically supervised. Benzodiazepines should be stabilised beforehand and not tapered concurrently, and substituting illicit short-acting opioids is explicitly discouraged

Three honesty markers belong alongside that protocol:

1. These are consensus harm-reduction guidelines from an advocacy body — not regulatory guidance, and not validated in any controlled trial. The gap between "about six days" and "eighteen or more days" reflects genuine uncertainty, not clinical precision
2. The transition itself carries risk: it means deliberately reintroducing a full agonist to someone stable on a partial agonist, before any ibogaine is given
3. Extended-release buprenorphine is a different problem entirely. After steady state, reached at roughly four to six months of monthly dosing, plasma buprenorphine may remain detectable for 12 months or longer after a final Sublocade injection. In a case series by Hayes and colleagues (Drug and Alcohol Dependence Reports, 2025), 15 people who stopped long-acting injectable buprenorphine showed withdrawal signs peaking at a median of six weeks after the last dose

For anyone asking about ibogaine after Sublocade: no clearance interval has been established, residual drug may persist for many months, and no published protocol addresses this scenario.

Because ibogaine is Schedule I in the United States, people seeking it travel to clinics where it is unscheduled or tolerated — most commonly Mexico, and also Costa Rica and Portugal. Oversight varies widely, there is no binding accreditation standard, and none of these programmes are approved treatments for buprenorphine discontinuation.

A responsibly run programme should include, at minimum:

• 12-lead ECG with QTc measurement, and cardiology clearance for any abnormality
• Comprehensive metabolic panel with serum potassium and magnesium, corrected before dosing
• Liver and renal function testing, full blood count, and pregnancy testing
• Complete medication reconciliation, screening for QT-prolonging and serotonergic agents
• CYP2D6 genotyping where available, to identify poor metabolisers with prolonged noribogaine exposure

For someone coming off Suboxone specifically, additional steps are not optional:

• A documented, supervised transition off buprenorphine with urine verification of elimination
• Benzodiazepine and alcohol assessment — unmanaged sedative withdrawal is independently dangerous
• Overdose-risk counselling and take-home naloxone, because opioid tolerance is reset
• A concrete aftercare plan agreed before travel, not improvised afterward

The acute course involves several hours of intense psychoactive effects followed by extended recovery, commonly with profound ataxia, nausea, vomiting, and inability to stand unassisted for many hours. Continuous cardiac telemetry is standard practice, and the monitoring window matters: noribogaine's long half-life means QT effects outlast the subjective experience, and the 2026 Molecules review documents cases in which QTc prolongation persisted for 7 to 12 days after exposure.

Ibogaine's safety profile is dominated by cardiac electrophysiology, and for people leaving buprenorphine there is a second, equally serious risk layer.

The mechanism. Ibogaine and noribogaine block hERG potassium channels in cardiomyocytes. The 2026 scoping review describes hERG/IKr inhibition as "a primary liability intrinsic to the ibogaine scaffold," reducing repolarisation reserve and creating substrate for malignant arrhythmia.

The magnitude. One observational trial reported average QT prolongation of 95 ms, with 50% of subjects exceeding a QTc of 500 ms. Case reports document peak QTc values above 600 ms, including one at 714 ms, with torsades de pointes and ventricular fibrillation. For scale, methadone — itself a recognised QT risk — prolongs QTc by roughly 10–15 ms.

The outcomes. Alper and colleagues documented 19 fatalities temporally associated with ibogaine between 1990 and 2008; a 2016 toxicology review identified at least 27. Causality is often confounded by pre-existing cardiovascular disease and polysubstance use, and deaths occurred predominantly in unregulated settings.

Documented cardiac risk factors include hypokalaemia and hypomagnesaemia, pre-existing cardiac or hepatic disease, polysubstance use (methadone, benzodiazepines, other opioids, alcohol), and CYP2D6 poor-metaboliser status.

Risks specific to leaving buprenorphine — additive to the cardiac risk, not alternatives to it:

• Loss of a documented mortality protection. All-cause mortality is roughly six times higher in the four weeks after stopping opioid agonist treatment
• Tolerance reset and overdose. The ibogaine clinical guidelines state plainly that a patient who returns to opioid use after treatment must be treated as opioid-naive. In a fentanyl-dominant supply, a single miscalculated dose can be fatal
• The pre-treatment transition window, during which a stable patient is moved back onto a full agonist
• Concurrent QT-prolonging psychiatric medications common in this population — SSRIs, SNRIs, trazodone, quetiapine, hydroxyzine — carrying additive QT and serotonergic interaction risk
• Benzodiazepine co-dependence, common alongside OUD and a contraindication until independently stabilised

Generally accepted absolute contraindications include known long QT syndrome, structural heart disease, heart failure, recent myocardial infarction, uncorrected electrolyte abnormalities, significant hepatic or renal impairment, pregnancy, active psychosis or bipolar I disorder, and concurrent MAOI or strongly serotonergic medication.

Legal status. Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act — the most restrictive category, denoting high abuse potential, no currently accepted medical use, and lack of accepted safety under medical supervision. It is not approved for opioid use disorder, or for buprenorphine discontinuation, anywhere in the world.

The policy landscape is moving. Texas Senate Bill 2308 authorises state matching funds for an FDA-approved clinical drug trial run by a public university with pharmaceutical and hospital partners, targeting opioid use disorder, depression and PTSD, with particular attention to veterans. Several other states have introduced research legislation. None of this changes federal scheduling, and none of it constitutes evidence of efficacy.

What would actually advance this question:

• Trials that enrol buprenorphine-maintained participants. Extrapolating from heroin and oxycodone cohorts is an assumption, not a finding
• A validated clearance interval. The gap between a six-day and an eighteen-day transition is unresolved, and there is no published guidance at all for extended-release buprenorphine
• Comparative data against slow taper and naltrexone-facilitated discontinuation — the realistic alternatives
• Mortality as a pre-specified endpoint. Given the sixfold post-cessation mortality signal, any programme that ends maintenance must measure deaths, not only abstinence
• Biologically confirmed, consistently defined outcomes, replacing self-report and heavy attrition
• Structured aftercare and relapse-window protection, which remain almost entirely unstudied

The honest bottom line. Ibogaine has a reproducible short-term effect on opioid withdrawal across several open-label cohorts. It has never been tested against placebo, never been studied in buprenorphine-maintained patients, and carries a documented risk of fatal arrhythmia. Buprenorphine maintenance, meanwhile, has some of the strongest mortality evidence in addiction medicine. The burden of proof here is high, and it has not been met.

---

This page is educational information, not medical advice. It does not recommend ibogaine or endorse any clinic. Decisions about starting, continuing, tapering, or stopping buprenorphine should be made with a prescribing clinician. Stopping opioid agonist treatment abruptly or without a plan substantially increases the risk of overdose death.